Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IONP-TNA@Man (also known as IONP-TNA@MA) is a d-mannose-modified iron oxide-tannic acid nanoparticle designed for the photothermal treatment of bacterial infections, particularly those caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (E. coli). The nanoparticle is synthesized via a tannic acid (TNA)-assisted hydrothermal reaction that converts iron oxide nanopowder (IONP) into black colloidal Fe3O4 nanoparticles, which are subsequently modified with d-mannose. The d-mannose moiety targets the FimH adhesin on the bacterial membrane, allowing the nanoparticles to adhere specifically to E. coli. Upon exposure to near-infrared (NIR) light (e.g., 808 nm), the nanoparticles exhibit high photon-to-thermal conversion, generating localized heat that destroys the bacteria with minimal cytotoxicity to human urothelial cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IONP-TNA@Man.